Literature DB >> 3612559

Evidence that uncharged verapamil inhibits myocardial contractility.

L Cohen, D Vereault, J A Wasserstrom, G S Retzinger, F J Kezdy.   

Abstract

The object of this study was to determine the molecular species of verapamil (Vp) which is responsible for the negative inotropic activity of the drug. Toward this end, we developed a model system which allowed us to determine the concentrations of protonated and neutral Vp and four congeners in solution and bound to an amphiphilic interface. We then determined the effect of Vp and these congeners on twitch tension in sheep trabecular muscle and correlated species abundance with biologic activity. The cumulative log dose-response curves of Vp, acyano-Vp and nor-Vp were sigmoidal. The concentrations of drug which were required to inhibit twitch tension by 50% (IC50) were 1000 +/- 240, 3350 +/- 620 and 7140 +/- 950 nM, respectively (mean +/- S.D.; P less than .01). Quaternary-Vp, an amphiphilic, nonionizable protonated derivative, produced some nonspecific inhibition which never reached 50%. Tetrahydroxy-Vp, a hydrophilic ionizable derivative, was inactive. Concentrations of the membrane-bound, neutral form of Vp, acyano-Vp and nor-Vp were comparable at their IC50 values (86 +/- 19, 104 +/- 19 and 121 +/- 16 nM, respectively; mean +/- S.D.; P, N.S.). In contrast, the concentrations of the membrane-bound, protonated form were significantly different and accounted for the "apparent" difference in the IC50 values. Based on these data, we conclude that: 1) ionizability and amphiphilicity are required for the negative inotropic effects of verapamil, acyano-Vp and nor-Vp; 2) twitch tension correlates best with the concentration of the membrane-bound neutral form of each drug; and 3) the potency differences between Vp, acyano-Vp and nor-Vp, as reflected by their IC50 values, are apparent, not real.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3612559

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Semi-rigid analogues of the calcium antagonist verapamil: a molecular modelling study.

Authors:  M N Romanelli; S Dei; S Scapecchi; E Teodori; F Gualtieri; R Budriesi; R Mannhold
Journal:  J Comput Aided Mol Des       Date:  1994-04       Impact factor: 3.686

2.  Comparison of lowest energy conformations of dimethylcurine and methoxyverapamil: evidence of ternary association of calcium channel, Ca2+, and calcium entry blockers.

Authors:  B S Zhorov
Journal:  J Membr Biol       Date:  1993-08       Impact factor: 1.843

3.  Differential inhibition of neuronal calcium entry and [3H]-D-aspartate release by the quaternary derivatives of verapamil and emopamil.

Authors:  R A Keith; T J Mangano; P A DeFeo; G E Ernst; E J Warawa
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

4.  The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts.

Authors:  J P Clozel; M Véniant; W Osterrieder
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

5.  Antiarrhythmic calcium channel blocker verapamil inhibits trek currents in sympathetic neurons.

Authors:  S Herrera-Pérez; L Rueda-Ruzafa; A Campos-Ríos; D Fernández-Fernández; J A Lamas
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.